An observational study in Stroke, Acute, sponsored by National Cerebral and Cardiovascular Center, Japan. Active, not recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by National Cerebral and Cardiovascular Center, Japan · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Stroke with a site in Japan — 7 open to participants now, 12 under way, 3 of them phase 3. Stroke · Japan.
Among the 69 studies in Stroke with a site in Japan, this one is the 6th largest by enrollment of the 15 observational ones that give a count, is one of 5 that started in 2016, is one of 15 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 41st registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →7 of the 69 studies in Stroke with a site in Japan are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Japan, United States, Canada
Ages 18+
Tokyo Women's Medical University · Sites in Japan
Ages 18+
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 35 more countries
Ages 50+
Nippon Medical School · Sites in Japan
Ages 18+
Hokkaido University Hospital · Sites in Japan
Ages 20–70
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 27 · Phase 4 9
First in 1996; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,374 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 834 across the 54 interventional studies, 3,026 across the 15 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 69 have an industry lead sponsor. The 10 most frequent:
National Cerebral and Cardiovascular Center, Japan is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
National Cerebral and Cardiovascular Center, Japan has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Stroke with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT02251665National Cerebral and Cardiovascular Center, JapanNational Cerebral and Cardiovascular Center (NCVC) Stroke Registry | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 69 studies in Stroke with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A single-center registry of patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack (TIA) who are emergently managed in the stroke care unit in the National Cerebral and Cardiovascular Center (NCVC) to determine change in underlying characteristics, stroke features and severity, process for diagnosis and acute treatment, and long-term outcomes of stroke/TIA patients over the years.
This is a single-center registry of consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack (TIA) who are emergently managed in the stroke care unit in the National Cerebral and Cardiovascular Center, a flagship stroke center in Japan.
Neurological emergencies other than stroke/TIA and subclinical cerebrobvascular inpatients are also enrolled.
Data are collected and analyzed to determine change in underlying characteristics, stroke features and severity, process for diagnosis and acute treatment, and long-term outcomes of stroke/TIA patients over the years.
The National Cerebral and Cardiovascular Center was founded in 1977 in Suita, Osaka, in order to provide the public with the most advanced treatment for cardiovascular and cerebrovascular diseases and to conduct the highest level of basic as well as applied research on the cardiovascular and cerebrovascular systems.
Inpatients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
Other: No intervention
a single-center prospective observational study
The modified Rankin Scale (mRS), a measure of disability
mRS scores range from 0 (no symptoms at all) to 6 (death)
Time frame: 3 monhts
Number of participants
Also assessing underlying patients' characteristics prior to index stroke/TIA
Time frame: at entry
National Institutes of Health Stroke Scale score
Also assessing neurological and cognitive states
Time frame: at entry
Volume of culprit infarcts/hematoma
ASPECTS on DWI for ischemia or hematoma volume using the ABC/2 method
Time frame: at entry
The modified Rankin Scale (mRS), a measure of disability
mRS scores range from 0 (no symptoms at all) to 6 (death). Participants will be followed at hospital discharge, an expected average of 3 weeks.
Time frame: around 3 weeks
The modified Rankin Scale (mRS), a measure of disability
mRS scores range from 0 (no symptoms at all) to 6 (death)
Time frame: 1 year
Events of cardiovascular diseases including stroke/TIA
Participants will be followed at hospital discharge, an expected average of 3 weeks.
Time frame: around 3 weeks
Events of cardiovascular diseases including stroke/TIA
Time frame: 3 months
Events of cardiovascular diseases including stroke/TIA
Time frame: 1 year
Started Oct 2016 (actual). Primary completion is estimated for Mar 2027, 125 months after the start.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 125 months is above that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cerebral and Cardiovascular Center, Japan